...
首页> 外文期刊>Journal of the American Geriatrics Society >Effect of Exposure to Evidence-Based Pharmacotherapy on Outcomes After Acute Myocardial Infarction in Older Adults
【24h】

Effect of Exposure to Evidence-Based Pharmacotherapy on Outcomes After Acute Myocardial Infarction in Older Adults

机译:循证药物治疗对老年人急性心肌梗死后结局的影响

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To assess the effect of exposure to evidence-based medication after hospital discharge for Medicare beneficiaries with acute myocardial infarction (AMI).DESIGN: A discrete-time hazard model was used to estimate time to outcome associated with exposure to four drug classes (angiotensin-con verting enzyme inhibitors (ACEIs)/angiotensin-II receptor blockers (ARBs), beta-block-ers (BBs), statins, and clopidogrel) used for post-AMI secondary prevention of cardiovascular events and mortality. SETTING: Medicare administrative data for a 5% random sample of beneficiaries.PARTICIPANTS: Medicare beneficiaries (N = 9,538) hospitalized for an AMI between April 1, 2006, and December 31, 2007, who survived for at least 30 days after discharge. The cohort was followed until death or December 31, 2008.MEASUREMENTS: Time-varying exposure was measured as proportion of days covered (PDC) for each quarter during the follow-up period. PDC was classified into five categories (0-0.2, 0.2-0.4, 0.4-0.6, 0.6-0.8, 0.8-1.0). Outcomes were mortality and a composite outcome of death or post-AMI hospitalization.RESULTS: Over a median follow-up of 18 months, mean PDC rates ranged from 0.37 (clopidogrel) to 0.50 (statins). When comparing the highest versus lowest categories of exposure, the hazard of the composite outcome was significantly lower for all drug classes except BBs (statins, adjusted hazard ratio (aHR) = 0.71, ACEIs/ARBs, aHR = 0.81, clopidogrel, aHR = 0.85, BBs, aHR = 0.93). All four drug classes were significantly associated with reductions in mortality; the magnitude of effect for the mortality outcome was largest for statins and smallest for BBs. Age modified the effect of statins on mortality. CONCLUSION: Use of evidence-based medications for secondary prevention after AMI is suboptimal in the Medicare population, and low exposure rates are associated with significantly higher risk for subsequent hospitalization and death.
机译:目的:评估出院后对急性心肌梗死(AMI)受益人的循证药物治疗的效果。设计:采用离散时间危害模型来估计与四种药物暴露相关的预后时间(血管紧张素转换酶抑制剂(ACEIs)/血管紧张素II受体阻滞剂(ARBs),β受体阻滞剂(BBs),他汀类药物和氯吡格雷)用于AMI后二级预防心血管事件和死亡率。地点:5%受益人随机抽样的Medicare行政数据。对象:2006年4月1日至2007年12月31日期间因AMI住院的Medicare受益人(N = 9,538),他们在出院后至少存活了30天。追踪该人群直至死亡或2008年12月31日。测量:随时间变化的暴露以随访期内每个季度的天数(PDC)的比例来衡量。 PDC分为五类(0-0.2、0.2-0.4、0.4-0.6、0.6-0.8、0.8-1.0)。结果是死亡率和死亡或AMI后住院的复合结果。结果:在中位随访18个月中,平均PDC率介于0.37(氯吡格雷)至0.50(他汀类药物)之间。当比较最高和最低暴露类别时,除BBs外,所有药物类别的复合结局风险均显着降低(他汀类药物,调整后的危险比(aHR)= 0.71,ACEI / ARBs,aHR = 0.81,氯吡格雷,aHR = 0.85 ,BBs,aHR = 0.93)。所有四种药物均与死亡率降低显着相关。他汀类药物对死亡率结果的影响程度最大,BB类药物对死亡率的影响程度最小。年龄改变了他汀类药物对死亡率的影响。结论:在Medicare人群中,AMI后使用循证药物进行二级预防并不理想,而且低暴露率与随后住院和死亡的风险显着相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号